Positron Emission Tomography Scans Obtained for the Evaluation of Cognitive Dysfunction

Seminars in Nuclear Medicine

Volumn 38, Issue 4, 2008, Pages 251-261

  Silverman, Daniel H S ^a   Mosconi, Lisa ^b   Ercoli, Linda ^a   Chen, Wei ^a,c   Small, Gary W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ALPHA TOCOPHEROL; CARBON 14; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; FDDNP F 18; FLUORODEOXYGLUCOSE F 18; MEMANTINE; MPPF F 18; PIB C 11; RADIOPHARMACEUTICAL AGENT; SELEGILINE; TISSUE PLASMINOGEN ACTIVATOR; WATER O 15;

AGING; ALLELE; ALZHEIMER DISEASE; AMNESIA; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN OXYGEN CONSUMPTION; BRAIN REGION; BRAIN SCINTISCANNING; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG UPTAKE; GLUCOSE UTILIZATION; HISTOPATHOLOGY; HUMAN; MEMORY DISORDER; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; REVIEW; SENILE PLAQUE; SOCIOECONOMICS; STROKE; TRANSIENT ISCHEMIC ATTACK;

BRAIN; COGNITION DISORDERS; HUMANS; IMAGE ENHANCEMENT; MOLECULAR PROBE TECHNIQUES; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 44249097034     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.02.006     Document Type: Review

References (102)

1. Ferri C.P., Prince M., Brayne C., et al. Global prevalence of dementia: A Delphi consensus study. Lancet 366 (2005) 2112-2117
2. Alzheimer's Association: Alzheimer's Disease Facts and Figures. http://www.alz.org/alzheimers_disease_facts_figures.asp Accessed March 12, 2008
3. Powell M.R., Smith G.E., Knopman D.S., et al. Cognitive measures predict pathologic Alzheimer disease. Arch Neurol 63 (2006) 865-868
4. Callahan C.M., Hendrie H.C., and Tierney W.M. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 122 (1995) 422-429
5. Hoffman R.S. Diagnostic errors in the evaluation of behavioral disorders. JAMA 248 (1982) 964-967
6. Lim A., Tsuang D., Kukull W., et al. Clinico-neuropathological correlation of AD in a community-based case series. J Am Geriatr Soc 47 (1999) 564-569
7. McDaniel L.D., Lukovits T., and McDaniel K.D. AD: The problem of incorrect clinical diagnosis. J Geriatr Psychiatry Neurol 6 (1993) 230-234
8. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1143-1153
9. Birks J., Iakovidou V., and Tsolaki M. Rivastigmine for AD. Cochrane Database Systemic Review. The Cochrane Library 4 (2000) :CD001191. (Available from: Update Software Ltd., Oxford, U.K. Accessed August 30, 2000)
10. Burns A., Rossor M., Hecker J., et al., International Donepezil Study Group. The effects of donepezil in AD: Results from a multinational trial. Dementia 10 (1999) 237-244
11. Corey-Bloom J., Anand R., Veach J., and ENA 713 B352 Study Group. A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe AD. Int J Geriatr Psychopharmacol 1 (1998) 55-65
12. Knapp M.J., Knopman D.S., Solomon P.R., et al. A 30-week randomized controlled trial of high-dose tacrine in patients with AD. The Tacrine Study Group. JAMA 271 (1994) 985-991
13. Raskind M.A., Peskind E.R., Wessel T., et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54 (2000) 2261-2268
14. Rogers S.L., Friedhoff L.T., Apter J.T., et al. The efficacy and safety of donepezil in patients with AD: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7 (1996) 293-303
15. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of Rivastigmine in patients with AD: International randomized controlled trial. BMJ 318 (1999) 633-638
16. Knopman D., Schneider L.S., Davis K., et al. Long-term tacrine (Cognex) treatment effects on nursing home placement and mortality. The Tacrine Study Group. Neurology 47 (1996) 166-177
17. Small G.W., Donohue J.A., and Brooks R.L. An economic evaluation of donepezil in the treatment of AD. Clin Ther 20 (1998) 838-850
18. Sano M., Ernesto C., Thomas R.G., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for AD. N Engl J Med 336 (1997) 1216-1222
19. Coyle J., and Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: Effects on the course of AD. Biol Psychiatry 49 (2001) 289-299
20. Morris J.C., Cyrus P.A., Orazem J., et al. Metrifonate benefits cognitive, behavioral, and global function in patients with AD. Neurology 50 (1998) 1222-1230
21. Tariot P., Solomon P., Morris J., et al., Galantamine Study Group. A 5-month, randomized, placebo-conrtrolled trial of galantamine in AD. Neurology 54 (2000) 2269-2276
22. Weiner M.F., Martin-Cook K., Foster B.M., et al. Effects of donepezil on emotional/behavioral symptoms in AD patients. J Clin Psychiatry 61 (2000) 487-492
23. Fago J.P. Dementia: Causes, evaluation, and management. Hosp Pract (Off Ed) 36 (2001) 59-69
24. Imbimbo B.P., Verdelli G., Martelli P., et al. Two-year treatment of AD with eptastigmine. Dement Geriatr Cogn Disord 10 (1999) 139-147
25. Rogers S.L., and Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of AD: An interim analysis of the results of a US multicentre open label extension Study. Eur Neuropsychopharmacol 8 (1998) 67-75
26. Doody R.S., Geldmacher D.S., Gordon B., et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Donepezil Study Group. Arch Neurol 58 (2001) 427-433
27. Jonker C., Geerlings M.I., and Schmand B. Are memory complaints predictive for dementia?. A review of clinical and population-based studies. Int J Geriatr Psychiatry 15 (2000) 983-991
28. Jorm A.F., Butterworth P., Anstey K.J., et al. Memory complaints in a community sample aged 60-64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med 34 (2004) 1495-1506
29. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: Theory, procedure and normal values in the conscious and anesthesized albino rat. J Neurochem 28 (1977) 897-916
30. Huang S.C., Phelps M.E., Hoffman E.J., et al. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238 (1980) E69-E82
31. 3. Ann Neurol 8 (1980) 47-60
32. Mazziotta J.C., Phelps M.E., Miller J., et al. Tomographic mapping of human cerebral metabolism: normal unstimulated state. Neurology 31 (1981) 503-516
33. Phelps M.E., Huang S.C., Hoffman E.J., et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxyglucose: Validation of method. Ann Neurol 6 (1979) 371-388
34. 18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44 (1979) 127-137
35. Moeller J.R., Ishikawa T., Dhawan V., et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 16 (1996) 385-398
36. Yamaji S., Ishii K., Sasaki M., et al. Evaluation of standardized uptake value to assess cerebral glucose metabolism. Clin Nucl Med 25 (2000) 11-16
37. Schultz S.K., O'Leary D.S., Boles Ponto L.L., et al. Age-related changes in regional cerebral blood flow among young to mid-life adults. Neuroreport; 10 (1999) 2493-2496
38. Meltzer C.C., Cantwell M.N., Greer P.J., et al. Does cerebral blood flow decline in healthy aging?. A PET study with partial-volume correction. J Nucl Med 41 (2000) 1842-1848
39. Mazziotta J.C., and Phelps M.E. Positron emission tomography studies of the brain. In: Phelps M., Mazziotta J., and Schelbert H. (Eds). Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart (1986), Raven Press, New York, NY 493-579
40. Apostolova L.G., Dinov I.D., Zoumalan C., et al. MR-Guided 3D PET Mapping of Longitudinal Changes in Regional Cerebral Metabolism of Normal Subjects (2006) International Conference on Alzheimer's Disease (ICAD2006), Madrid, (abstr)
41. Silverman D.H.S., Small G.W., Chang C.Y., et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
42. Herholz K., Nordberg A., Salmon E., et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 10 (1999) 494-504
43. Minoshima S., Giordani B., Berent S., et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42 (1997) 85-94
44. Silverman D.H.S. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45 (2004) 594-607
45. Silverman D.H.S., Truong C.T., Kim S.K., et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab 80 (2003) 350-355
46. Small G.W., Ercoli L.M., Silverman D.H., et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97 (2000) 6037-6042
47. Bench C.J., Friston K.J., Brown R.G., et al. Regional cerebral blood flow in depression measured by positron emission tomography: The relationship with clinical dimensions. Psychol Med 23 (1993) 579-590
48. Petersen R.C., Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol 58 (2001) 1985-1992
49. de Leon M.J., Convit A., Wolf O.T., et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98 (2001) 10966-10971
50. Jack C.R., Peterson R.C., Xu Y., et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55 (2000) 484-489
51. Rusinek H., De Santi S., Frid D., et al. Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology 229 (2003) 691-696
52. Jack Jr. C.R., Shiung M.M., Gunter J.L., et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62 (2004) 591-600
53. den Heijer T., Geerlings M.I., Hoebeek F.E., et al. Use of hippocampal and amygdala volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 63 (2006) 57-62
54. Chetelat G., Desgranges B., Landeau B., et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 131 (2008) 60-71
55. Mosconi L., Tsui W.H., De Santi S., et al. Reduced hippocampal metabolism in mild cognitive impairment and Alzheimer's disease: Automated FDG-PET image analysis. Neurology 64 (2005) 1860-1867
56. Ibanez V., Pietrini P., Alexander G.E., et al. Regional gluose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 50 (1999) 1585-1593
57. Nestor P.J., Fryer T.D., Smielewski P., et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 54 (2003) 343-351
58. Mosconi L., De Santi S., Li Y., et al. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med 33 (2006) 210-221
59. Chetelat G., Desgranges B., de la Sayette V., et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 60 (2003) 1374-1377
60. Drzezga A., Lautenschlager N., Siebner H., et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: A PET follow-up study. Eur J Nucl Med Mol Imaging 30 (2003) 1104-1113
61. Arnaiz E., Jelic V., Almkvist O., et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12 (2001) 851-855
62. Drzezga A., Grimmer T., Riemenschneider M., et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005 46 (2005) 1625-1632
63. Anchisi D., Borroni B., Franceschi M., et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62 (2005) 1728-1733
64. Evans D.A., Beckett L.A., Field T.S., et al. Apolipoprotein E epsilon-4 and incidence of Alzheimer disease in a community population of older persons. JAMA 277 (1997) 822-824
65. Small G.W., Mazziotta J.C., Collins M.T., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273 (1995) 942-947
66. Reiman E.M., Caselli R.J., Yun L.S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. N Eng J Med 334 (1996) 752-758
67. Reiman E.M., Chen K., Alexander G.E., et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101 (2004) 284-289
68. Silverman D.H.S., Hussain S.A., Ercoli L.M., et al. Detection of differences in regional cerebral metabolism associated with genotypic and educational risk factors for dementia (2000) 422-427 Proceedings of the International Conference on Mathematics and Engineering Techniques in Medicine and Biological Sciences
69. Benson D.F., Kuhl D.E., Phelps M.E., et al. Positron emission computed tomography in the diagnosis of dementia. Trans Am Neurol Assoc 106 (1981) 68-71
70. 18F-2-deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia. Am J Psychiatry 139 (1982) 352-353
71. Foster N.L., Chase T.N., Fedio P., et al. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 33 (1983) 961-965
72. Frackowiak R.S., Pozzilli C., Legg N.J., et al. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104 (1981) 753-778
73. Devous Sr. M.D. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med Mol Imaging 29 (2002) 1685-1696
74. Small G.W., Bookheimer S.Y., Thompson P.M., et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol & (2008) 161-172
75. Silverman D.H.S., and Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin N Am 43 (2005) 67-77
76. Silverman D.H.S., Small G.W., and Phelps M.E. Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of AD. Clin Positron Imaging 2 (1999) 119-130
77. Mielke R., Schroder R., Fink G.R., et al. Regional cerebral glucose metabolism and postmortem pathology in AD. Acta Neuropathol (Berl) 91 (1996) 174-179
78. Salmon E., Sadzot B., Maquet P., et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 35 (1994) 391-398
79. Tedeschi E., Hasselbalch S.G., Waldemar G., et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 59 (1995) 608-615
80. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41 (2000) 1920-1928
81. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 5 suppl (2001) 1S-93S
82. Knopman D.S., DeKosky S.T., Cummings J.L., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56 (2001) 1143-1153
83. Ackerman R.H., Correia J.A., Alpert N.M., et al. Positron imaging in ischemic stroke disease using compounds labeled with oxygen-15. Initial results of clinicophysiologic correlations. Arch Neurol 38 (1981) 537-543
84. 15O positron tomography. Stroke 12 (1981) 454-459
85. Grubb Jr. R.L., Derdeyn C.P., Fritsch S.M., et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 280 (1998) 1055-1060
86. Yamauchi H., Fukuyama H., Nagahama Y., et al. Significance of increased oxygen extraction fraction in five-year prognosis of major cerebral arterial occlusive diseases. J Nucl Med 40 (1999) 1992-1998
87. Heiss W.D., Grond M., Thiel A., et al. Tissue at risk of infarction rescued by early reperfusion: A positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab 18 (1998) 1298-1307
88. Marchal G., Benali K., Iglesias S., et al. Voxel-based mapping of irreversible ischaemic damage with PET in acute stroke. Brain 122 (1999) 2387-2400
89. Nemoto E.M., Yonas H., Pindzola R.R., et al. PET OEF reactivity for hemodynamic compromise in occlusive vascular disease. J Neuroimaging 17 (2007) 54-60
90. Endo H., Inoue T., Ogasawara K., et al. Quantitative assessment of cerebral hemodynamics using perfusion-weighted MRI in patients with major cerebral artery occlusive disease: Comparison with positron emission tomography. Stroke 37 (2006) 388-389
91. Takasawa M., Jones P.S., Guadagno J.V., et al. How reliable is perfusion MR in acute stroke?. Validation and determination of the penumbra threshold against quantitative PET. Stroke (2008) E-pub Feb 7, PMID: 18258831
92. Price J.L., and Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45 (1999) 358-368
93. Shoghi-Jadid K., Small G.W., Agdeppa E.D., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry 10 (2002) 24-35
94. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
95. Small G.W., Kepe V., Ercoli L., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355 (2006) 2652-2663
96. Kemppainen N.M., Aalto S., Wilson I.A., et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68 (2007) 1603-1606
97. Pappata S., Salvatore E., and Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging 18 (2008) 111-124
98. Kepe V., Barrio J.R., Huang S.C., et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci U S A 103 (2006) 702-707
99. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol; 56 (1999) 303-308
100. Alexander G.E., Chen K., Pietrini P., et al. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159 (2002) 738-745
101. Reiman E.M., Caselli R.J., Chen K., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 98 (2001) 3334-3339
102. Small G.W., Silverman D.H.S., Siddarth P., et al. Effects of a 14-day healthy aging lifestyle program on cognition and brain function. Am J Geriatr Psychiatry 14 (2006) 538-545